Skip to content
My WebMD Sign In, Sign Up

Cancer Health Center

Font Size

New Strategy Helps Young Lymphoma Patients

Approach resulted in high remission rates without the risks tied to radiotherapy, researchers say

continued...

In the study, only two patients who received this dose-adjusted chemotherapy treatment did not go on to achieve complete remission. These two patients, the researchers noted, also received radiation and have not had their tumors come back.

Meanwhile, none of the patients who did achieve a complete remission experienced disease recurrence. The researchers added there were no signs of heart damage or other long-term negative health effects among the patients.

"The high success of this regimen in greatly reducing the need for radiation and improving the cure rate in this disease may relate to specialized dosing and continuous infusion delivery of the EPOCH-R agents," explained lead researcher Dr. Wyndham Wilson, head of the NCI's Lymphoma Therapeutics Section.

Wilson and his colleagues also collaborated with researchers at Stanford University who used the regimen to treat their own group of 16 slightly older patients with primary mediastinal B-cell lymphoma. The Stanford study found all 16 patients who received the dose-adjusted chemotherapy regimen achieved full remission and none of them required radiation.

Other experts were optimistic about the research.

"What is encouraging is the fact that so many patients did well without radiotherapy, which will reduce the risk these patients have of developing late complications, including secondary solid tumors, acute leukemia and cardiac disease," said Dr. Jonathan Kolitz, associate chief of hematological oncology at the North Shore-LIJ Cancer Institute in Lake Success, N.Y. He stressed, however, that more research needs to be done to confirm that the new approach "is truly superior to the more conventional administration" used today.

Dr. Alan Astrow is director of hematology/medical oncology at Maimonides Cancer Center in New York City. He called the findings "highly impressive results."

"It appears that radiation therapy is not required for patients with primary mediastinal B-cell lymphoma who achieve a complete response after treatment with the reported chemotherapy regimen," he said.

For his part, Brody said the new results are exactly what most physicians long to see.

"Oncologists go into this business to try to save lives but, truthfully, the opportunity to save the lives of young, healthy people, and give them back a whole lifetime of quality time . . . is particularly gratifying," Brody said.

1|2

Today on WebMD

Building a Support System
Blog
cancer fighting foods
SLIDESHOW
 
precancerous lesions slideshow
SLIDESHOW
quit smoking tips
SLIDESHOW
 
Jennifer Goodman Linn self-portrait
Blog
what is your cancer risk
HEALTH CHECK
 
colorectal cancer treatment advances
Video
breast cancer overview slideshow
SLIDESHOW
 
prostate cancer overview
SLIDESHOW
lung cancer overview slideshow
SLIDESHOW
 
ovarian cancer overview slideshow
SLIDESHOW
Actor Michael Douglas
Article